Efficacy and Safety of Indacaterol Plus Tiotropium Versus Tiotropium Alone in Patients With Chronic Obstructive Pulmonary Disease
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- First Posted Date
- 2009-04-07
- Last Posted Date
- 2011-08-25
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 1142
- Registration Number
- NCT00877383
- Locations
- 🇺🇸
Novartis Investigative site, Philadelphia, Pennsylvania, United States
🇨🇿Novartis Investigative SIte, Liberec, Czech Republic
🇭🇺Novartis Investgative Site, Százhalombatta, Hungary
Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2009-04-06
- Last Posted Date
- 2018-12-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 719
- Registration Number
- NCT00876395
- Locations
- 🇺🇸
Comprehensive Blood and Cancer Center Dept. of CBCC (2), Bakersfield, California, United States
🇺🇸New York Oncology Hematology NYOH Amsterdam, Albany, New York, United States
🇺🇸Texas Oncology Charles A. Sammons Cancer Ctr, Dallas, Texas, United States
Efficacy and Safety of Deferasirox in Non-transfusion Dependent Thalassemia Patients With Iron Overload and a One Year Open-label Extension Study
- Conditions
- Non-transfusion Dependent Thalassemia
- Interventions
- Drug: placebo
- First Posted Date
- 2009-04-01
- Last Posted Date
- 2013-07-09
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 166
- Registration Number
- NCT00873041
- Locations
- 🇺🇸
Children's Memorial Hospital/Division of Hematology/Oncology, Chicago, Illinois, United States
🇺🇸New York Presbyterian Hospital/Weill Medical College of Cornell University, New York, New York, United States
🇺🇸Children's Hospital & Research Center Oakland, Oakland, California, United States
Evaluate the Effect of Omalizumab on Markers of Asthma Impairment in Patients With Persistent Allergic Asthma
- First Posted Date
- 2009-03-27
- Last Posted Date
- 2011-11-17
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 271
- Registration Number
- NCT00870584
- Locations
- 🇺🇸
Palm Spring Research Institute, Inc, Hialeah, Florida, United States
🇺🇸Paul A Shapero, MD, Bangor, Maine, United States
🇺🇸Pediatric Pulmonary Associates of North Texas, PA, Dallas, Texas, United States
Five Year Adjuvant Imatinib Mesylate (Gleevec®) in Gastrointestinal Stromal Tumor (GIST)
- First Posted Date
- 2009-03-23
- Last Posted Date
- 2018-03-14
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 91
- Registration Number
- NCT00867113
- Locations
- 🇺🇸
Washington Hospital Center Department of Medical Oncology, Washington, District of Columbia, United States
🇺🇸Longstreet Cancer Center, Gainesville, Georgia, United States
🇺🇸Penn State University / Milton S. Hershey Medical Center Penn Stat University, Hershey, Pennsylvania, United States
Efficacy and Safety of Pazopanib Monotherapy After First Line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
- First Posted Date
- 2009-03-20
- Last Posted Date
- 2021-02-16
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 940
- Registration Number
- NCT00866697
- Locations
- 🇨🇳
Novartis Investigative Site, Taipei, Taiwan
A Study of the Safety and Preliminary Efficacy of Oral Midostaurin (PKC412) in Relapsed or Refractory Pediatric Leukemia
- Conditions
- Acute Lymphoblastic LeukemiaAcute Myeloid Leukemia
- Interventions
- First Posted Date
- 2009-03-20
- Last Posted Date
- 2015-12-22
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 22
- Registration Number
- NCT00866281
- Locations
- 🇺🇸
Seattle Children's Hospital CPKC412A2114, Seattle, Washington, United States
🇸🇪Novartis Investigative Site, Stockholm, Sweden
Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2009-03-18
- Last Posted Date
- 2017-05-02
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 724
- Registration Number
- NCT00863655
- Locations
- 🇺🇸
University of Texas Southwestern Medical Center SimmonsComprehensiveCancerCtr., Dallas, Texas, United States
🇺🇸Mercy Medical Center Medical Oncology & Hematology, Baltimore, Maryland, United States
🇺🇸Crescent City Research Consortium, LLC Dept of Hem&Onc Specialist - 2, Metairie, Louisiana, United States
Efficacy of Telbivudine in Blacks/African Americans and Hispanics/Latinos With Compensated Chronic Hepatitis B During 52 Weeks
- Conditions
- Compensated Chronic Hepatitis B
- Interventions
- Drug: Telbivudine/LDT600A
- First Posted Date
- 2009-03-17
- Last Posted Date
- 2016-09-23
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT00862706
- Locations
- 🇺🇸
Liver Specialist of Texas, Houston, Texas, United States
🇺🇸Tufts Medical Center, Boston, Massachusetts, United States
🇺🇸Hepatobiliary Associates of New York, Bayside, New York, United States
A Study Investigating the Renal Tolerability, Efficacy, and Safety of a CNI-free Versus a Standard Regimen in de Novo Heart Transplant (HTx) Recipients
- Conditions
- Heart Transplantation
- Interventions
- First Posted Date
- 2009-03-17
- Last Posted Date
- 2018-08-07
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 162
- Registration Number
- NCT00862979
- Locations
- 🇩🇪
Novartis Investigative Site, Regensburg, Germany